Skip to main content

2 Result(s)

within Laurence Buisseret Remove this filter Science, Humanities and Social Sciences, multidisciplinary Remove this filter

and

  1. Article

    Open Access

    Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

    Laurence Buisseret, Delphine Loirat, Philippe Aftimos… in Nature Communications (2023)

    Download PDF (464 KB) View Article

  2. Article

    Open Access

    Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

    Chemo-immunotherapy is the first-line standard of care for patients with PD-L1 positive metastatic triple-negative breast cancer (mTNBC). SYNERGY (NCT03616886) is a dose-finding phase I and a randomized phase ...

    Laurence Buisseret, Delphine Loirat, Philippe Aftimos… in Nature Communications (2023)

    Download PDF (2370 KB) View Article